INVESTIGATION OF CROSS IMMUNITY FOLLOWING VACCINATION WITH ALLOGENIC CANCER CELL

同种异体癌细胞疫苗接种后交叉免疫的研究

• 批准号: 7376297
• 负责人: PAUL O SCHWARZENBERGER
• 金额: $ 1.98万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376297
• 关键词: INVESTIGATION; CROSS; IMMUNITY; FOLLOWING; VACCINATION

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We are currently conducting a lung cancer clinical vaccine trial which is using gene modified cancer cells. The design of this ongoing vaccine study is geared to investigate whether immunity specifically directed against the allogenic cell lines used as the actual vaccine will develop. Appropriate assays will be performed which includes cytotoxic T-lymphocyte assays, as well as cytokine assays and clinical evaluation for tumor responses. Participating subjects already have provided appropriate consents. In order to perform additional important immunological assays from archived blood, we propose and investigator initiated component. We propose to examine whether a response against other lung cell lines has developed. This response would be specifically against cell lines the subjects had not been vaccinated during the vaccination process. These studies will be performed on lymphocytes and serum obtained from naive subjects (prior to vaccination) and subjects following each of the four vaccinations. These tissues and serum are archived and cryopreserved and propsed studies will be conducted in vitro.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。我们目前正在进行一项使用基因修饰癌细胞的肺癌临床疫苗试验。这项正在进行的疫苗研究的设计旨在调查是否会产生专门针对用作实际疫苗的同种异体细胞系的免疫力。将进行适当的检测，包括细胞毒性 T 淋巴细胞检测、细胞因子检测和肿瘤反应的临床评估。参与受试者已经提供了适当的同意。为了从存档的血液中进行其他重要的免疫学测定，我们提出了由研究者发起的组件。我们建议检查是否已产生针对其他肺细胞系的反应。这种反应将专门针对受试者在疫苗接种过程中未接种疫苗的细胞系。这些研究将对从初次受试者（疫苗接种前）和四次疫苗接种后的受试者获得的淋巴细胞和血清进行。这些组织和血清被存档和冷冻保存，并支持在体外进行研究。